Wang Mao-sheng, Li Jun, Di Hai-xia, Li Zhen-li, Yang Shu-Lian, Hou Wei, Yan Jin-yu, Zhao Xiao-min
TCM Hospital of Langfang City, Chinese Hemopathic Therapeutic Center of TCM, Hebei, 065000, China.
Chin J Integr Med. 2007 Jun;13(2):98-102. doi: 10.1007/s11655-007-0098-5.
To observe the clinical effect of Astragalus Injection (, AI) and its immuno-regulatory action in treating chronic aplastic anemia (CAA).
Sixty patients with CAA were randomly assigned to two groups equally, both were treated with Stanozolol three times a day, 2 mg each time through oral intake, but AI was given additionally to the patients in the treated group once a day via intravenous dripping. All were treated for 15 days as one therapeutic course and the whole medication lasted for more than 4 months totally, with follow-up adopted. The clinical efficacy was estimated and the changes of T-lymphocyte subsets in peripheral blood as well as the serum levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-2 (IL-2) were observed.
The total effective rate in the treated group was 83.3% (25/30), which was higher than that in the control group 66.7% (20/30), showing significant difference between them (P<0.05). Levels of hemoglobin, WBC, reticular cell and platelet were elevated in both groups after treatment, but the improvement was significantly better in the treated group than that in the control group with respect to the former three indexes (P<0.05). The level of CD4(+) increased and that of CD8(+) decreased significantly after treatment in the treated group (P<0.05), which showed significant difference as compared with those in the control group (P<0.05). Levels of serum TNF-alpha and IL-2 lowered after treatment in both groups, but significance only showed in the treated group (P<0.05). The degree of proliferation in bone marrow got raised significantly and the percentage of non-hemopoietic cells reduced significantly in the treated group after treatment, also showing significant difference to those in the control group (P<0.05).
AI could promote the recovery of hemopoietic function, which might be through improving T-lymphocyte subsets and reducing the release of negative regulatory factors such as TNF-alpha and IL-2 to alleviate the inhibition on hemopoietic function.
观察黄芪注射液（AI）治疗慢性再生障碍性贫血（CAA）的临床疗效及其免疫调节作用。
将60例CAA患者随机分为两组，每组各30例。两组患者均口服司坦唑醇，每日3次，每次2mg；治疗组患者加用黄芪注射液，每日1次，静脉滴注。两组均以15天为1个疗程，全疗程用药4个月以上，并进行随访。观察两组患者的临床疗效、外周血T淋巴细胞亚群变化以及血清肿瘤坏死因子-α（TNF-α）和白细胞介素-2（IL-2）水平。
治疗组总有效率为83.3%（25/30），高于对照组的66.7%（20/30），两组比较差异有统计学意义（P<0.05）。两组治疗后血红蛋白、白细胞、网织红细胞及血小板水平均升高，但治疗组前三项指标改善情况明显优于对照组（P<0.05）。治疗组治疗后CD4(+)水平升高，CD8(+)水平显著降低（P<0.05），与对照组比较差异有统计学意义（P<0.05）。两组治疗后血清TNF-α和IL-2水平均降低，但仅治疗组差异有统计学意义（P<0.05）。治疗组治疗后骨髓增殖程度明显提高，非造血细胞比例显著降低，与对照组比较差异有统计学意义（P<0.05）。
黄芪注射液可促进造血功能恢复，其机制可能是通过改善T淋巴细胞亚群，减少TNF-α、IL-2等负性调节因子的释放，减轻对造血功能的抑制。
